In CAPS patients with hyperactive NLRP3 variants, targeted therapies inhibiting the NLRP3 inflammasome or neutralizing excessive pro-inflammatory cytokines have shown promising results in clinical trials [88,89]. The gene discussed is NLRP3; the disease is cryopyrin-associated periodic syndrome.